Skip to content

Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients

Prevalence of Asymptomatic and Symptomatic Infection of N. Gonorrheae and C. Trachomatis and Seroprevalence of HSV Typ 2 and Sexual Health Seeking Behaviour in People With HIV Infection in Bern

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00973466
Acronym
CTNG
Enrollment
300
Registered
2009-09-09
Start date
2009-05-31
Completion date
2010-06-30
Last updated
2011-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chlamydia Trachomatis, Herpes Simplex, HIV Infections, Neisseria Gonorrhoeae

Keywords

HIV-infection, Neisseria gonorrhea, Chlamydia trachomatis, Herpes simplex virus, prevalence

Brief summary

There has been an increase in incidence in sexually transmitted infections in HIV infected patients in the last years. In this study the investigators will prospectively evaluate the prevalence of symptomatic and asymptomatic infections with N. gonorrhea and Ch. trachomatis as well as the seroprevalence of Herpes simplex Type 2 infection in HIV-infected patients attending the clinic for infectious diseases at the Berne University Hospital. In addition, participants will be asked to fill out a questionnaire on sexual behaviour and sexual health. Study hypothesis: STI prevalence is high in certain risk-groups to justify screening in regular intervals.

Interventions

None listed

Sponsors

Pfizer
CollaboratorINDUSTRY
Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV-infection * Attending the Clinic for Infectious Diseases from May 09 to November 09 * Sexually active during the last 12 months * Written informed consent

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Prevalence of infection with C.trachomatis, N. gonorrhea and Seroprevalence of HSV 2 infection6 months

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026